INTRODUCTION {#s1}
============

Oxidative DNA damage leads to formation of 8-oxoguanine, which during DNA replication, results in 8-OxoG:A mispairing and subsequent C:G\>A:T transversion mutations ([@MCS003681THIC20]; [@MCS003681THIC4]). The MUTYH DNA glycosylase excises mismatched adenine from the 8-OxoG:A complex ([@MCS003681THIC7]). Colorectal tumors from patients with germline biallelic *MUTYH* aberrations and *MUTYH*-associated polyposis (MAP) feature base excision repair (BER) deficiency mutational signatures enriched for C:G\>A:T transversion mutations ([@MCS003681THIC37]). Novel associations of this transversion signature have also been identified in a subset of germline *MUTYH* carriers with pancreatic neuroendocrine tumors and adrenocortical tumors displaying somatic inactivation of the second allele ([@MCS003681THIC24]; [@MCS003681THIC30]).

We report a case of early-onset pancreatic ductal adenocarcinoma (PDAC) in a patient harboring biallelic *MUTYH* germline mutations, whose tumor featured somatic mutational signatures consistent with defective *MUTYH*-mediated BER and the associated driver *KRAS* transversion mutation p.Gly12Cys. Analysis of an additional 730 advanced cancer cases (*N* = 731) was undertaken to determine whether the mutational signatures were also present in tumors from germline *MUTYH* heterozygote carriers or if instead the signatures were seen only in those with biallelic loss of function. This review of our cohort revealed two female patients with breast cancer each carrying a single heterozygous pathogenic germline *MUTYH* variant associated with loss of heterozygosity (LOH) in the tumor and the same somatic signatures. Therefore, we describe three cases with germline or combined germline/somatic biallelic *MUTYH* aberrations and C:G\>A:T mutational signatures previously linked to defective *MUTYH* in tumors not classically associated with MAP syndrome. These novel associations illustrate that both biallelic and a monoallelic *MUTYH* pathogenic germline variants can contribute to the mutational landscape of an individual\'s cancer and should therefore be considered when elevated somatic C:G\>A:T transversion signatures possibly suggestive of *MUTYH* deficiency (e.g., COSMIC Signature 18, SigProfiler SBS18/SBS36, SignatureAnalyzer SBS18/SBS36) are identified.

RESULTS {#s2}
=======

Genomic profiling of a PDAC case with germline biallelic compound heterozygous *MUTYH* variants revealed markedly elevated Catalogue of Somatic Mutations in Cancer (COSMIC) Signature 18. These findings prompted review of our entire cohort of advanced cancers (*N* = 731) for *MUTYH* status and mutational signatures. Briefly, tumor with matched normal blood whole-genome sequencing (WGS) and tumor whole-transcriptome sequencing was performed in 731 patients with advanced cancers of diverse origins ([Supplemental Table S1A](http://www.molecularcasestudies.org/lookup/suppl/doi:10.1101/mcs.a003681/-/DC1)). Mutational signatures were analyzed using the R package signIT ([@MCS003681THIC41]), and the reference matrices from COSMIC ([@MCS003681THIC2]; [@MCS003681THIC12]), SigProfiler ([@MCS003681THIC3]), and SignatureAnalyzer ([@MCS003681THIC14]) (please refer to Methods and [Supplemental Methods](http://www.molecularcasestudies.org/lookup/suppl/doi:10.1101/mcs.a003681/-/DC1) for details).

Biallelic Germline *MUTYH* Variants and Pancreatic Ductal Adenocarcinoma {#s2a}
------------------------------------------------------------------------

### Clinical History {#s2a1}

We report a female (Patient \#1) of Chinese ancestry initially diagnosed with Stage IIB distal PDAC at the age of 45 yr.

Of note, the patient had a prior colonoscopy and gastroscopy at age 43 for epigastric pain, which reported three colonic tubular adenomas, one rectal tubular adenoma, and one gastric fundic gland polyp. She was evaluated at the Hereditary Cancer Program for her early-onset PDAC and positive family history of gastrointestinal cancers. Her father was diagnosed with pancreatic cancer at the age of 79 yr. Her brother was diagnosed with colorectal cancer on a reported background of 30 tubular adenomas at the age of 54 yr ([Supplemental Fig. S1](http://www.molecularcasestudies.org/lookup/suppl/doi:10.1101/mcs.a003681/-/DC1) for pedigree).

Distal pancreatectomy and partial splenectomy revealed a 6-cm moderately differentiated ductal adenocarcinoma within the pancreatic tail ([Supplemental Fig. S2](http://www.molecularcasestudies.org/lookup/suppl/doi:10.1101/mcs.a003681/-/DC1)). Margins were clear, but there was lymphovascular and perineural invasion as well as one of four lymph nodes involved. There was no evidence of intratumoral lymphocytes. The final pathologic stage was pT2N1. The patient\'s primary tumor was assessed for DNA mismatch repair protein expression by immunohistochemistry and intact staining was noted in the *MLH1*, *MSH2*, *MSH6*, and *PMS2* proteins (data not shown).

She received adjuvant chemotherapy with 5-fluorouracil, oxaliplatin, and irinotecan on a clinical trial and completed all 12 planned cycles. Posttreatment imaging and CA19-9 showed no evidence of disease recurrence. Three months after completing adjuvant chemotherapy, routine surveillance CT detected signs of local recurrence. Patient \#1 received radiotherapy to the pancreatic remnant, 50 Gy in 25 fractions, with concurrent capecitabine. Restaging FDG-PET performed 1 mo after completion of therapy revealed multiple liver metastases. The patient consented to participate in the Personalized OncoGenomics study and underwent ultrasound-guided liver biopsy, which confirmed the diagnosis of metastatic PDAC.

She commenced first-line palliative chemotherapy with gemcitabine and nab-paclitaxel and had an excellent radiological partial response and biochemical response after six cycles of treatment. Six months later, she was switched to nivolumab for progression, but she did not respond to immunotherapy. The patient unfortunately passed away from complications of her metastatic disease at age 48.

### Germline Analysis {#s2a2}

Clinical germline genetic testing identified compound heterozygote pathogenic variants in *MUTYH* (c.996G\>A, p.Ser332Ser and c.815G\>A, p.Gly272Glu; NM_001048171). Blood DNA WGS with analysis of 98 cancer predisposition genes also identified the *MUTYH* variants ([Table 1](#MCS003681THITB1){ref-type="table"}) and no other pathogenic variants ([Table 1](#MCS003681THITB1){ref-type="table"}; [Supplemental Table S1B,C](http://www.molecularcasestudies.org/lookup/suppl/doi:10.1101/mcs.a003681/-/DC1)). Somatic transcriptome data showed the synonymous variant to cause abnormal splicing and the pathogenic variants to be in *trans* (see Somatic Analysis below).

###### 

*MUTYH* pathogenic germline single-nucleotide variants (SNVs) and somatic *MUTYH* status

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------
  General   Germline   Somatic                                                                                                                                   
  --------- ---------- -------------------- ------------- ------------- ----------------- ------------- --------- -------------- --------- --------- ---- ------ --------
  \#1       PAAD       Chr 1:45797481C\>T   c.996G\>A     p.Ser332Ser   Synonymous        rs372673338   Neutral   Heterozygous   26/53     2/15      16   5683   0.4702

  \#1       PAAD       Chr 1:45797914C\>T   c.815G\>A     p.Gly272Glu   Missense          rs730881833   Neutral   Heterozygous   18/45     20/29     16   5683   0.4702

  \#2       IDC        Chr 1:45797760T\>C   c.892-2A\>G                 Splice acceptor   rs77542170    Loss      Homozygous     33/49     80/121    56   830    0.1668

  \#3       IDC        Chr 1:45797228C\>T   c.1145G\>A    p.Gly382Asp   Missense          rs36053993    Loss      Homozygous     49/55     113/125   20   1735   0.0857

  \#4       ACC        Chr 1:45797228C\>T   c.1145G\>A    p.Gly382Asp   Missense          rs36053993    Neutral   Heterozygous   22/51     NA        NA   308    0.2081

  \#5       ATRT       Chr 1:45798475T\>C   c.494A\>G     p.Tyr165Cys   Missense          rs34612342    Neutral   Heterozygous   biop2:\   biop2:\   23   76     0.0536
                                                                                                                                 33/74\    41/75\                
                                                                                                                                 biop1:\   biop1:\               
                                                                                                                                 27/68     52/101                

  \#6       LUAD       Chr 1:45797760T\>C   c.892-2A\>G                 Splice acceptor   rs77542170    Neutral   Heterozygous   37/67     9/28      18   50     0.0059

  \#7       RCC        Chr 1:45798475T\>C   c.494A\>G     p.Tyr165Cys   Missense          rs34612342    Gain      Heterozygous   37/76     59/126    22   20     0.0047

  \#8       IDC        Chr 1:45798475T\>C   c.494A\>G     p.Tyr165Cys   Missense          rs34612342    Gain      Heterozygous   62/90     91/120    56   21     0.0029

  \#9       ULMS       Chr 1:45797760T\>C   c.892-2A\>G                 Splice acceptor   rs77542170    Neutral   Heterozygous   50/101    84/221    69   46     0.0056

  \#10      PAAD       Chr 1:45797760T\>C   c.892-2A\>G                 Splice acceptor   rs77542170    Neutral   Heterozygous   45/95     72/231    72   23     0.0031

  \#11      PAAD       Chr 1:45797760T\>C   c.892-2A\>G                 Splice acceptor   rs77542170    Loss      Heterozygous   19/44     13/50     37   18     0.0011

  \#12      LUAD       Chr 1:45797760T\>C   c.892-2A\>G                 Splice acceptor   rs77542170    Neutral   Heterozygous   19/44     36/97     58   48     0.0028
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------

Variant annotations with GRCh37 (hg19) genomic positions and *MUTYH* transcript NM_001048171 positions. All variants are heterozygous in the germline. The Cancer Genome Atlas (TCGA) *MUTYH* expression percentile is provided in comparison to the TCGA average for all cancers. COSMIC Signature 18 (Sig18) exposures are shown in this table, please refer to [Supplemental Tables S2--S4](http://www.molecularcasestudies.org/lookup/suppl/doi:10.1101/mcs.a003681/-/DC1) for complete mutational signatures profiles using reference matrices from COSMIC, SigProfiler, and Signature Analyzer.

(ACC) Adrenocortical carcinoma, (ATRT) atypical teratoid/rhabdoid tumor, (IDC) breast invasive ductal carcinoma, (LUAD) lung adenocarcinoma, (NA) not available, (PAAD) pancreatic adenocarcinoma, (RCC) renal cell carcinoma, (TCGA) The Cancer Genome Atlas, (ULMS) uterine leiomyosarcoma.

### Somatic Analysis {#s2a3}

A tetraploid model (four copies) with an estimated tumor content of 51% was used for the PDAC. Tumor genomic features such as single-nucleotide variants (SNVs), indels, structural variants (SVs), copy-number variants (CNVs), and mutational signatures were analyzed in conjunction with gene expression from transcriptome data. In comparison to The Cancer Genome Atlas (TCGA) data set, the overall coding mutational burden was moderate with 88 coding SNVs (73rd percentile for all TCGA cancers and 76th percentile for TCGA pancreatic cancers) and six coding indels (73rd percentile for all TCGA cancers and first percentile for TCGA pancreatic cancers). The total number of somatic SNVs (coding and noncoding) for Patient \#1 was 12087, or 3.78 SNVs per Mb. There were 86 SVs (60th percentile among our local database of 626 cancers of diverse origins). Please refer to [Supplemental Table S2A--D](http://www.molecularcasestudies.org/lookup/suppl/doi:10.1101/mcs.a003681/-/DC1) for additional genomic data.

As mentioned previously, tumor transcriptome data showed the germline variants to be in *trans* and expressed ([Fig. 1](#MCS003681THIF1){ref-type="fig"}A). The targeted assembly pipeline (TAP) ([@MCS003681THIC9]) on the transcriptome showed the synonymous germline variant (c.996G\>A, p.Ser332Ser) to create a novel canonical AG acceptor splice site removing 42 bp and 14 amino acids ([Fig. 1](#MCS003681THIF1){ref-type="fig"}B; [Supplemental Table S2E](http://www.molecularcasestudies.org/lookup/suppl/doi:10.1101/mcs.a003681/-/DC1)). Because of the creation of this novel acceptor splice site and subsequent splicing out of the c.996G\>A variant, the variant was only present in two out of 15 RNA-seq reads spanning the Chr 1:45797481 genomic site. The second pathogenic variant (c.815G\>A, p.Gly272Glu) was present in 20 out of 29 RNA-seq reads covering the Chr 1:45797914 genomic site. The novel exon junction at Chr 1:45797479 was supported by 12 reads, whereas the canonical junction at Chr 1:45797521 was supported by 19 reads ([Supplemental Table S2E](http://www.molecularcasestudies.org/lookup/suppl/doi:10.1101/mcs.a003681/-/DC1)).

![Patient \#1 compound heterozygous *MUTYH* germline variants. (*A*) Integrated Genomics Viewer (IGV) ([@MCS003681THIC35]) capture of whole-genome sequencing of tumor and matched blood DNA with whole-transcriptome sequencing of tumor RNA data at the genomic region encompassing the two *MUTYH* variants (c.996G\>A, p.Ser332Ser and c.815G\>A, p.Gly272Glu; NM_001048171). Paired-end transcriptome reads showing the germline variants to be in *trans* with read pairs containing the p.Gly272Glu variant (exon 10) but not the p.Ser332Ser variant (exon 12) (red box). The splicing aberration caused by p.Ser332Ser variant was not visually apparent in IGV and required transcriptome TAP for detection and characterization. TAP was used to assemble reads into contigs. Contig 1 shows aberrant splicing and contig 2 shows normal splicing. (*B*) Schematic of TAP analysis results showing the synonymous germline variant (c.996G\>A, p.Ser332Ser) creating a novel canonical AG acceptor splice site at Chr 1:45797480--45797481 and removing 42 bp (14 amino acids).](MCS003681Thi_F1){#MCS003681THIF1}

The PDAC tumor featured the highest Signature 18 and SBS36 signatures of our cohort using three different published signatures references matrices (COSMIC, SigProfiler, and SignatureAnalyzer) with a proportion of mutations contributed of 41%--48% (4962--5769 SNVs) ([Figs. 2](#MCS003681THIF2){ref-type="fig"} and [3](#MCS003681THIF3){ref-type="fig"}; [Supplemental Table S2F--H](http://www.molecularcasestudies.org/lookup/suppl/doi:10.1101/mcs.a003681/-/DC1)). *KRAS* increased expression (94th percentile compared to the TCGA average) was associated with copy gains (+3 copies) and the driver *KRAS* p.Gly12Cys (c.34G\>T, NM_033360) transversion mutation (3/6 copies). Given the predicted mutational signatures probability from each reference matrix, the Bayesian probability ([Supplemental Table S2I](http://www.molecularcasestudies.org/lookup/suppl/doi:10.1101/mcs.a003681/-/DC1)) for the *KRAS* transversion mutation to be caused by the transversion signatures previously associated with *MUTYH* deficiency is 84% for Signature 18 (COSMIC), 75% for combined SBS18/SBS36 signatures (SigProfiler), and 62% for combined SBS18/SBS36 signatures (SignatureAnalyzer).

![Comparison of mutation signatures exposures of *MUTYH* germline or combined germline/somatic biallelic aberrations against 731 cancer genomes of mixed origins. The cohort distribution of mutation signature exposures for each signature is shown using signature composition reference matrices from COSMIC, SigProfiler, and SignatureAnalyzer. The mutation fraction exposures (proportion of all mutations contributed by each signature) of Patient \#1, Patient \#2, and Patient \#3 are superimposed. Signatures previously associated with *MUTYH*-mediated BER deficiency are highlighted by a rectangle. Patient \#1 (PDAC, pink diamond), Patient \#2 (breast cancer, green diamond), and Patient \#3 (breast cancer, blue diamond) demonstrated germline or combined germline/somatic biallelic *MUTYH* aberrations. Functional biallelic *MUTYH* loss of function was present in tumors of Patient \#1, Patient \#2, and Patient \#3 and all three patients displayed elevated outlier (\>1.5 interquartile range above third quartile) signatures previously associated with defective *MUTYH* (COSMIC Signature 18, SigProfiler SBS18 and SBS36, and SignatureAnalyzer SBS18 and SBS36).](MCS003681Thi_F2){#MCS003681THIF2}

![Mutation catalogs and COSMIC mutational signatures of *MUTYH* germline or combined germline/somatic biallelic aberrations. Complete catalogs of SNVs from WGS of tumors were classified based on variant and 3′/5′ contexts into 96 categories (*left* side) and mutation catalogs were used to calculate the contribution of each signature to mutational burden (*right* side). The proportion of mutations or mutation count in each of the 96 categories is shown here as a barplot (*left* side), whereas the signIT Markov Chain Monte Carlo simulation result for COSMIC mutational signatures is shown as a violin plot distribution (*right* side). COSMIC Signature 18 composition is shown at the top for reference. Patient \#1 (germline *MUTYH* c.815G\>A, p.Gly272Glu; c.996G\>A, p.Ser332Ser; NM_001048171) and Patient \#2 (germline *MUTYH* c.892-2A\>G) tumors showed increased Signature 18 somatic mutation burden, as exemplified by the resemblance of their mutation catalogs to COSMIC reference Signature 18. Other mutational processes contributed most to the mutational burden of Patient \#3\'s tumor.](MCS003681Thi_F3){#MCS003681THIF3}

The tumor harbored several somatic events that have previously been associated with PDAC ([@MCS003681THIC5]). A 10-Mb deletion at 9p led to homozygous copy loss of tumor-suppressor genes (TSGs) *CDKN2A*, *CDKN2B*, and *MTAP*, and a 51-Mb deletion at 18q led to heterozygous copy loss of TSGs *SMAD2* and *SMAD4*. In addition to the gain-of-function (GOF) *KRAS* mutation (p.Gly12Cys), somatic small mutations of interest included the *TP53* frameshift indel with a deletion copy loss leading to biallelic loss of function, as well as heterozygous frameshift indels in two epigenetic TSGs: *ARID1A* and *SETD2*. Including subclonal variants, 53/95 (56%) of moderate to high impact variants in protein coding genes were due to tranversion events ([Supplemental Table S2C](http://www.molecularcasestudies.org/lookup/suppl/doi:10.1101/mcs.a003681/-/DC1)). Fusions of potential biological relevance included a Chr 12 duplication leading to an inversion-fusion of *GPRC5A* and *CCDC91* associated with a copy gain (+2 copies) and elevated *GPRC5A* expression (96th percentile compared to the TCGA average). BER pathway genes *OGG1* and *NUDT1* had low percentile expression (third percentile for both) and *OGG1* had a copy loss (−1 copy). Please refer to [Supplemental Table S2](http://www.molecularcasestudies.org/lookup/suppl/doi:10.1101/mcs.a003681/-/DC1) for additional genomic data.

Germline *MUTYH* Carriers with Somatic Second Hits in Breast Cancer {#s2b}
-------------------------------------------------------------------

Analysis of an additional 730 advanced cancer cases (*N* = 731) was undertaken to determine whether the mutational signatures seen in Patient \#1\'s PDAC were also present in tumors from germline *MUTYH* heterozygote carriers or, if instead, the signatures were only seen in the case of biallelic loss of function.

Using reference matrices from COSMIC, SigProfiler, and SignatureAnalyzer, somatic mutational signatures were analyzed in terms of mutation counts (number of SNVs) and proportions (fraction between 0 and 1) contributed to the overall mutational burden. Mutation counts (mean exposures) and mutation fractions (proportion contributed by each signature) higher than 1.5 interquartile range above the third quartile were considered outliers. Among germline *MUTYH* carriers (*N* = 12; [Table 1](#MCS003681THITB1){ref-type="table"}) all three cases of biallelic *MUTYH* aberrations (Patient \#1, Patient \#2, and Patient \#3) were outliers for the proportion of mutations contributed by transversion signatures previously associated with defective *MUTYH* ([Figs. 2](#MCS003681THIF2){ref-type="fig"}, [3](#MCS003681THIF3){ref-type="fig"}; [Supplemental Tables S2F--H, S3F--H, S4E--G](http://www.molecularcasestudies.org/lookup/suppl/doi:10.1101/mcs.a003681/-/DC1)).

### Patient \#2 Overview {#s2b1}

Patient \#2 is a female patient of North-East Asian ancestry diagnosed with metastatic invasive ductal breast carcinoma (4 × 5-cm mass on ultrasound, Nottingham grade 2/3, estrogen receptor 8/8, progesterone receptor 7/8, and HER2^--^) at the age of 32 yr. Two bone lesions at L5 and T10 were seen on MRI and PET imaging. She was treated with doxorubicin and cyclophosphamide for six cycles, followed by mastectomy and axillary node resection. Family history was negative for MAP-associated cancers. Patient \#2 was found to carry a single germline *MUTYH* splice site variant (c.892-2A\>G; NM_001048171). No other pathogenic variants were identified on clinical multigene panel testing or analysis of 97 additional cancer susceptibility genes by WGS. Their tumor featured a somatic copy loss of *MUTYH* (triploid model, tumor content 38%), resulting in the splice site variant being homozygous in the tumor.

The tumor had an unremarkable coding mutational burden with 24 nonsynonymous coding SNVs (29th percentile among all TCGA cancers and 54th percentile among TCGA breast cancer data set), one coding indel (24th percentile among all TCGA cancers and 28th percentile among TCGA breast cancer data set), and 116 SVs (73rd percentile among our local database of 583 cancer cases) ([Supplemental Table S3A--D](http://www.molecularcasestudies.org/lookup/suppl/doi:10.1101/mcs.a003681/-/DC1)). The total number of somatic SNVs (coding and noncoding) for Patient \#2 was 4979, or 1.52 SNVs per Mb.

The targeted assembly pipeline (TAP) ([@MCS003681THIC9]) on the transcriptome showed two mechanisms of abnormal splicing associated with this germline variant. The first mechanism leads to a 9-bp deletion due to the canonical splice site acceptor disruption and selection of a downstream canonical AG acceptor splice site at Chr 1:45797750--45797751 (new exon start at Chr 1:45797749). The second mechanism leads to marked intron 10 and intron 11 retention ([Fig. 4](#MCS003681THIF4){ref-type="fig"}; [Supplemental Table S3E](http://www.molecularcasestudies.org/lookup/suppl/doi:10.1101/mcs.a003681/-/DC1)).

![Germline *MUTYH* founder Asian splice site variant impact on splicing. The Asian founder mutation *MUTYH* disrupting the canonical acceptor splice site at exon 11 (c.892-2A\>G) was found in six patients (Patient \#2, Patient \#6, Patient \#9, Patient \#10, Patient \#11, and Patient \#12). (*A*) Integrated Genomic Viewer (IGV) ([@MCS003681THIC35]) capture of whole-genome sequencing of tumor and matched blood DNA with whole-transcriptome sequencing of tumor RNA data at the genomic region encompassing the *MUTYH* variant (c.892-2A\>G; NM_001048171).Transcriptome data showing abnormal splicing removing 9 bp from exon 11 (19 reads with a black line) and marked intron 10 and intron 11 retention. (*B*) Schematic of abnormal splicing removing 9 bp from exon 11. (*C*) Schematic of abnormal splicing resulting in intron retention.](MCS003681Thi_F4){#MCS003681THIF4}

Despite the overall low mutation counts (4979 SNVs), the contribution of COSMIC Signature 18, SigProfiler SBS36, and SignatureAnalyzer SBS36 signatures was elevated ([Table 1](#MCS003681THITB1){ref-type="table"}; [Supplemental Table S3F--H](http://www.molecularcasestudies.org/lookup/suppl/doi:10.1101/mcs.a003681/-/DC1)), suggesting that some degree of *MUTYH*-mediated BER deficiency could be present in the tumor because of the combined germline and somatic biallelic *MUTYH* aberrations. COSMIC Signature 1 (1203 SNVs or 24.2% of all SNVs), associated with age, contributed most to overall mutational burden, followed by Signature 18 (830 SNVs or 16.7% of all SNVs) and nonspecific Signature 5 (757 SNVs or 15.2% of all SNVs) ([Figs. 2](#MCS003681THIF2){ref-type="fig"} and [3](#MCS003681THIF3){ref-type="fig"}; [Supplemental Table S4F--H](http://www.molecularcasestudies.org/lookup/suppl/doi:10.1101/mcs.a003681/-/DC1)).

Somatic genomic features of interest included *PIK3CA* p.His1047Arg (heterozygous, 2/3 copies) GOF mutation, *ADGRA2* amplification (+9 copies), *AKT1* copy gain (+1 copy), and *AKT3* amplification (+5 copies). Additional CNVs of potential clinical relevance included amplification of *MDM4* (+5 copies) and single-copy gains of *MDM2*, *CDK4*, *CDK6*, and *AURKA*. BER gene *OGG1* had low expression (second percentile), but both *OGG1* and *NUDT1* were copy neutral. Please refer to [Supplemental Table S3](http://www.molecularcasestudies.org/lookup/suppl/doi:10.1101/mcs.a003681/-/DC1) for additional data.

### Patient \#3 Overview {#s2b2}

Patient \#3 is a female patient of European ancestry diagnosed at the age of 69 yr with invasive left ductal breast carcinoma pT2N1aMX grade 3 (estrogen receptor/progesterone receptor positive, HER2^--^). She was initially treated with partial left mastectomy and left axillary lymph node dissection followed by standard care adjuvant therapy doxorubicin, cyclophosphamide, and paclitaxel, but paclitaxel was replaced by docetaxel following a severe allergic reaction to paclitaxel. This regimen was followed by adjuvant letrozole and radiation therapy (16 cycles). In addition to the pathogenic germline *MUTYH* variant (c.1145G\>A, p.Gly382Asp), this patient also carries a heterozygous pathogenic germline *CHEK2* mutation (NM_007194:c.1100delC, p.Thr367Metfs, rs555607708). Family history revealed a maternal aunt with premenopausal breast cancer at the age of 30 yr who underwent bilateral mastectomy.

The tumor had an elevated coding mutational burden with 92 nonsynonymous coding SNVs (74th percentile among all TCGA cancers and 93rd percentile among TCGA breast cancer data set), four coding indels (59th percentile among all TCGA cancers and 69th percentile among TCGA breast cancer data set), and 248 SVs (93rd percentile among our local database of 626 cancer cases) ([Supplemental Table S4A--D](http://www.molecularcasestudies.org/lookup/suppl/doi:10.1101/mcs.a003681/-/DC1)). The total number of somatic SNVs (coding and noncoding) for Patient \#3 was 20237, or 6.32 SNVs per Mb.

The tumor had a somatic *MUTYH* copy loss (triploid model, tumor content 70%) resulting in the germline variant being homozygous in the tumor. Although COSMIC Signature 18 had a significant contribution (1735 or 8.6% of all SNVs), Signature 2 (6621 or 32.7% of all SNVs) and Signature 13 (3512 or 17.4% of all SNVs), associated with the APOBEC family of cytidine deaminases, were the main contributors to overall mutational burden ([Table 1](#MCS003681THITB1){ref-type="table"}; [Figs. 2](#MCS003681THIF2){ref-type="fig"}, [3](#MCS003681THIF3){ref-type="fig"}; [Supplemental Tables S4A,E--G](http://www.molecularcasestudies.org/lookup/suppl/doi:10.1101/mcs.a003681/-/DC1)). Deletion copy loss (−1 copy) of *BRCA1* and *BRCA2* was observed in the tumor. Furthermore, the germline *CHEK2* c.1100delC heterozygous variant was homozygous in the tumor by reason of a somatic deletion LOH event. However, Signature 3, associated with homologous recombination deficiency, only very modestly contributed to overall mutational burden (304 or 1.5% of all SNVs).

Other somatic events of interest included copy gain (+2 copies) with *PIK3CA* p.His1047Arg (heterozygous, 4/5 copies) GOF mutation, *FGFR2* amplification (+58 copies), *CCND1* amplification (+19 copies), and *AKT3* amplification (+4 copies). Additional CNVs of potential clinical relevance included amplifications of *MDM4* (+8 copies), *MDM2* (+4 copies), *CDK2*/*CDK4* (+3 copies), and *AURKA* (+3 copies). BER pathway genes *NUDT1* and *OGG1* had low percentile expression (2nd and 15th percentile, respectively) and *NUDT1* had copy neutral LOH, whereas *OGG1* had a copy loss (−1 copy). Please refer to [Supplemental Table S4](http://www.molecularcasestudies.org/lookup/suppl/doi:10.1101/mcs.a003681/-/DC1) for additional data.

### MUTYH Asian Founder Splice Site Variant {#s2b3}

The Asian founder *MUTYH* splice site mutation c.892-2A\>G (rs77542170) ([@MCS003681THIC33]) was identified in six out of 731 patients (minor allele frequency 0.0041, or 0.41%). According to the gnomAD database, this splice site variant has a minor allele frequency of 0.11% (0.0011) in the general population and 1.5% (0.015) in the East Asian population ([@MCS003681THIC21]). Given the frequency of this variant in our cohort, we conducted single-nucleotide polymorphism principal component analysis using the EthSeq R package ([@MCS003681THIC25]) to show that all patients carrying this pathogenic germline variant were of East Asian ancestry ([Supplemental Table S5](http://www.molecularcasestudies.org/lookup/suppl/doi:10.1101/mcs.a003681/-/DC1)). The ethnic composition of our cohort explains the large number of carriers identified with the *MUTYH* c.892-2A\>G variant. Transcriptome TAP of the tumors from patients carrying the c.892-2A\>G splice site mutation consistently identified the same two abnormal splicing mechanisms described in [Figure 4](#MCS003681THIF4){ref-type="fig"} (other *MUTYH* carriers transcriptome assembly data not shown).

DISCUSSION {#s3}
==========

We observed mutational signatures featuring a strong C:G\>A:T transversion phenotype that have previously been associated with defective *MUTYH* in tumors from patients with biallelic germline or combined germline and somatic *MUTYH* loss of function (*N* = 3). Such signatures, collectively referred to as SBS18/SBS36 signatures, include COSMIC Signature 18, SigProfiler SBS18/SBS36, and SignatureAnalyzer SBS18/SBS36 ([@MCS003681THIC24]; [@MCS003681THIC30]; [@MCS003681THIC37]; [@MCS003681THIC3]). The study of Patient \#1 (germline compound heterozygote) provides evidence for the contribution of aberrant *MUTYH* function to the PDAC genomic landscape. Zhou et al. reported a high frequency of *KRAS* p.Gly12Cys transversion mutations in pancreatic cancer (80/126, 63%) ([@MCS003681THIC17]; [@MCS003681THIC11]; [@MCS003681THIC40]; [@MCS003681THIC42]). The *KRAS* p.Gly12Cys variant was seen in 2% of colorectal cancers, and, of those, 25% had germline biallelic pathogenic *MUTYH* variants ([@MCS003681THIC15]; [@MCS003681THIC1]). As activated *KRAS* is a frequent and early driver of PDAC, germline mutations in *MUTYH* have been hypothesized to be associated with development of pancreatic adenocarcinoma cancer on this basis, although this had not been demonstrated prior to our study ([@MCS003681THIC31]). Given the predominant contribution of SBS18/SBS36 signatures to the PDAC mutational landscape in the setting of germline biallelic *MUTYH* mutations (Patient \#1), the oncogenic driver *KRAS* transversion was likely caused by *MUTYH* deficiency. A Bayesian probability approach consistently ranked the transversion signatures previously associated with germline or combined germline/somatic *MUTYH* impairment (COSMIC Signature 18 \[[@MCS003681THIC24]; [@MCS003681THIC30]\], SigProfiler SBS36 \[[@MCS003681THIC3]\], and SignatureAnalyzer SBS36 \[[@MCS003681THIC3]\]) at the top ([Supplemental Table S2I](http://www.molecularcasestudies.org/lookup/suppl/doi:10.1101/mcs.a003681/-/DC1)).

In all the *MUTYH* mutation carriers (*n* = 9) in which a wild-type copy was retained in the tumor, SBS18/SBS36 signatures were not predominant or were inconsistent between the methods (COSMIC, SigProfiler, and SignatureAnalyzer). These results suggest that *MUTYH* is haplosufficient with respect to *MUTYH* function in a monoallelic state, but that biallelic complete loss of *MUTYH* function can cause SBS18/SBS36 signatures to arise even in tumors not classically associated with MAP syndrome ([Table 1](#MCS003681THITB1){ref-type="table"}).

We identified strong evidence for *MUTYH-*mediated BER deficiency contributing to oncogenesis in our PDAC case with germline biallelic *MUTYH* aberrations. Patient \#2 and Patient \#3 both carry a heterozygous germline *MUTYH* pathogenic variant (c.892-2A\>G and c.1145G\>A (p.Gly382Asp), respectively). and their breast cancer tumor displayed a somatic *MUTYH* copy loss causing the germline variant to become functionally homozygous (2/2 remaining copies, triploid model). While APOBEC signatures were the main contributors to Patient \# 3\'s mutational landscape, signatures associated with age contributed most to Patient \#2\'s somatic landscape. Although the SBS18/SBS36 signatures contribution remained modest in the two breast cancer cases accounting for 16.7%--19.8% and 8.9%--10.3% of all mutations in Patient \#2 and Patient \#3, respectively, the rarity of these characteristic signatures in the setting of combined germline and somatic biallelic *MUTYH* inactivation suggests that *MUTYH* deficiency is likely the main determinant of C:G\>A:T transversion mutations in these tumors. There is debate in the literature as to whether or not inactivation of *MUTYH* predisposes to breast cancer ([@MCS003681THIC38]; [@MCS003681THIC6]). Although evidence of somatic SBS18/SBS36 signatures in two breast cancer cases does not resolve this question, our findings suggest that germline *MUTYH* heterozygous mutations can occasionally contribute to somatic mutational evolution in the presence of secondary somatic *MUTYH* loss of function. Even though other known germline cancer predisposition variants such as the *CHEK2* c.1100delC in Patient \#3 are stronger determinants of lifetime breast cancer risk, a minor influence of germline *MUTYH* pathogenic variant carrier status cannot be excluded.

*MUTYH* is one of two BER DNA glycosylase genes that have been linked to recessive familial adenomatous polyposis syndromes and specific somatic mutational signatures. *NTHL1* is associated with a C:G\>T:A mutational phenotype ([@MCS003681THIC39]). *MUTYH* is associated with the 8-OxoG BER pathway and a C:G\>A:T transversion phenotype ([@MCS003681THIC37]). The 8-OxoG BER pathway is redundant and, therefore, it is possible that multiple genomics hits in this pathway, including *NUDT1* and *OGG1*, may be required for the SBS18/SBS36 C:G\>A:T transversion signatures to arise in presence of oxidative DNA damage. *NUDT1*-null mice showed increased tumorigenesis, but the number of spontaneous mutations was not increased compared to wild-type mice ([@MCS003681THIC36]). When the *NUDT1* knockout was superimposed on a mismatch repair--deficient background, tumors displayed enrichment for C:G\>A:T transversion mutations ([@MCS003681THIC10]). *OGG1*-null mice showed increased spontaneous tumorigenesis and transversion mutations ([@MCS003681THIC18]; [@MCS003681THIC22]; [@MCS003681THIC28]). However, double knockout of *OGG1* and *NUDT1* did not increase tumorigenesis, which suggests the oncogenic effects of *OGG1* deficiency may be counteracted by *NUDT1* deficiency ([@MCS003681THIC28]). Finally, *MUTYH*-null mice showed increased intestinal tumorigenesis and C:G\>A:T transversion mutations ([@MCS003681THIC27]). To date, germline variation in *OGG1* and *NUDT1* has not been associated with a Mendelian hereditary cancer predisposition, and *MUTYH* remains the only validated cancer predisposition gene linked to the SBS18/SBS36 signatures with a strong phenotype of C:G\>A:T transversions ([@MCS003681THIC23]).

Beyond consideration for defective BER as a potential underlying etiology, SBS18/SBS36 transversion signatures ultimately arise from an excess of reactive oxygen species (ROS) and subsequent formation of 8-oxoguanine (8-OxoG) ([@MCS003681THIC8]). Increased oxidative damage lead to C:G\>A:T transversion mutations even in the presence of intact *MUTYH*, but the frequency of such transversions is markedly increased by *MUTYH* deficiency ([@MCS003681THIC26]). [@MCS003681THIC32] recently suggested that *MUTYH* may actually increase C:G\>A:T transversions in presence of 8-Oxo-dGTP. In light of this, SBS18/SBS36 signatures are most likely multifactorial in origin and depend on the state of oxidative stress and metabolism, as well as on the functionality of *MUTYH* and BER mechanisms.

We identified several known pathogenic *MUTYH* founder mutations within our cohort as well as previously described pathogenic variants ([Table 1](#MCS003681THITB1){ref-type="table"}; NM_001048171). Founder variants included the European p.Gly382Asp and p.Tyr165Cys variants ([@MCS003681THIC20]; [@MCS003681THIC4]) and the Asian c.892-2A\>G variant ([@MCS003681THIC33]). Previously reported pathogenic variants included c.815G\>A (p.Gly272Glu) and c.996G\>A (p.Ser332Ser) ([@MCS003681THIC17]; [@MCS003681THIC11]; [@MCS003681THIC40]). Although classifications of c.996G\>A and c.892-2A\>G are less than uniform among reporting centers per ClinVar ([@MCS003681THIC19]), ranging from being a variant of uncertain significance to likely pathogenic or pathogenic, they are locally considered to be pathogenic alleles. The combined germline and somatic data presented herein support these classifications. The presence of markedly elevated SBS18/SBS36 transversion signatures in Patient \#1 associated with abnormal splicing of c.996G\>A and phasing of the biallelic compound heterozygous germline variants (c.996G\>A, p.Ser332Ser and c.815G\>A, p.Gly272Glu) support pathogenicity of the synonymous variant (p.Ser332Ser). Patient \#2 carries a heterozygous germline *MUTYH* variant (c.892-2A\>G) shown to cause aberrant splicing and their tumor featured somatic inactivation of the remaining allele resulting in biallelic *MUTYH* aberrations. The presence of the same transversion signatures in Patient \#2 also supports pathogenicity of the Asian founder variant c.892-2A\>G.

CONCLUSION {#s4}
==========

Our study demonstrates that tumors with biallelic *MUTYH* aberrations arising in the germline or combined germline and somatic contexts display a characteristic elevation of somatic C:G\>A:T transversion signatures previously associated with defective *MUTYH-*mediated BER. Defective *MUTYH* is not the sole determinant of these signatures, but *MUTYH* germline variants may be present in a subset of patients with tumors demonstrating mutational signatures possibly suggestive of *MUTYH* deficiency (e.g., COSMIC Signature 18, SigProfiler SBS18/SBS36, or SignatureAnalyzer SBS18/SBS36). Further research in large cohorts will be important to elucidate the role of germline and somatic *MUTYH* aberrations, in relation to BER deficiency in diverse cancer types, in particular within populations where founder mutations have been identified.

METHODS {#s5}
=======

Patient written informed consent was obtained for the Personalized OncoGenomics trial at BC Cancer (NCT02155621), which was approved by the University of British Columbia/BC Cancer Research Ethics Board. Tumor with matched normal blood WGS and tumor whole-transcriptome sequencing was performed in 731 patients with advanced cancers of diverse origins ([Supplemental Table S1A](http://www.molecularcasestudies.org/lookup/suppl/doi:10.1101/mcs.a003681/-/DC1)). The average depth of coverage was 80× and 40× for the tumor and normal genome, respectively. Library preparation, sequencing, and bioinformatics analyses were performed according to previously published protocols ([@MCS003681THIC34]). For each patient, tumor and matched normal samples were analyzed together to identify somatic LOH and copy-number alteration (CNA) regions using CNAseq (v0.0.8) ([@MCS003681THIC16]) and APOLLOH (v0.1.2) ([@MCS003681THIC13]) tools, which both utilize the hidden Markov model. The ensemble of LOH and CNA regions were compared to a set of theoretical ploidy models ranging from diploid to pentaploid and a set of theoretical tumor content varying by 10% intervals from the initial tumor content assessed on pathological examination. For example, if the tumor content was 44% on initial assessment, ploidy models (diploid, triploid, tetraploid, pentaploid) were assessed with theoretical tumor contents of 14%, 24%, 34%, 44%, 54%, 64%, 74%, 84%, and 94%. This results in a total collection of 40 models. The collected copy states are compared to the values for theoretical copy states in each model. The model which results in the lowest error and model complexity is selected upon manual review. Mutational burden was reported in terms of coding nonsynonymous mutation count as well as total SNVs count (coding and noncoding) and SNVs per Mb rate. The SNVs per Mb rate was calculated using an approximate hg19 genome assembly size of 3200 Mb. SV count (or SV mutational load) of a given case was compared to the cohort local database of SVs at the time of analysis. A case enrolled earlier in the study is compared to a smaller cohort (smaller local database) than a case enrolled later in the study (larger local database). Somatic mutations called by Strelka ([@MCS003681THIC29]) were classified into 96 classes based on the variant base and 3′ and 5′ context (trinucleotide). Using publicly available signatures reference matrices from COSMIC ([@MCS003681THIC2]), SigProfiler ([@MCS003681THIC3]), and SignatureAnalyzer ([@MCS003681THIC14]), the contribution of each signature was determined with the Bayesian R package signIT as previously described ([@MCS003681THIC41]).

To calculate the probability for driver *KRAS* transversion mutation (C\[C\>A\]A transversion leading to p.Gly12Cys) to be caused by signatures previously associated with *MUTYH* deficiency (COSMIC Signature 18, SigProfiler SBS18/SBS36, and SignatureAnalyzer SBS18/SBS36) in Patient \#1, Bayesian inference was used. For each signature, the posterior probability *P*(S\|M) for the mutation to be caused by that given signature was calculated as follows: $${P\left( S \middle| M \right)} = \mspace{7mu}{\frac{{P\left( M \middle| S \right) \times}P\left( S \right)}{P\left( M \right)},}$$ in which *P*(M\|S) is the prior probability of C\[C\>A\]A in the reference signature matrix, *P*(S) is the proportion of mutation contributed by this signature, and *P*(M) is the total number of C\[C\>A\]A events.

ADDITIONAL INFORMATION {#s6}
======================

Data Deposition and Access {#s6a}
--------------------------

Whole-genome sequencing and RNA-seq data (.bam files) for 11 out of 12 patients discussed in this study have been submitted to the European Genome-phenome Archive (EGA) ([www.ebi.ac.uk/ega/home](www.ebi.ac.uk/ega/home)) under data accession numbers EGAD00001002597 (Patient \#1), EGAD00001004710 (Patient \#2), EGAD00001004711 (Patient \#3), EGAD00001002037 (Patient \#4), EGAD00001002985 (Patient \#6), EGAD00001003023 (Patient \#7), EGAD00001003635 (Patient \#8), EGAD00001003733 (Patient \#9), EGAD00001004666 (Patient \#10), EGAD00001004713 (Patient \#11), and EGAD00001004714 (Patient \#12). Consent for data sharing does not allow for data deposition for Patient \#5. This work, including data deposition, was approved by the Research Ethics Board at the BC Cancer, protocols H12-00137 and H14-00681. Written consent was obtained from the patients after discussion with their oncologists.

Ethics Statement {#s6b}
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The Personalized OncoGenomics project was approved by the University of BC Cancer (BCCA) Research Ethics Board (REB) (protocols H12-00137 and H14-00681). Informed written consent was obtained from the patients for comprehensive tumor profiling with transcriptome sequencing (tumor) and whole-genome sequencing (tumor and blood). The use of data sets is allowed for research reports and scientific publications. The protocol allows for data to be not only used for research reports and scientific publication but also to be made available to named investigators of institutions who agree by a data transfer agreement stating they will honor the same ethical and privacy principles required by the BCCA REB. Following informed consent, the patients underwent tumor biopsies and peripheral blood sampling as part of the Personalized OncoGenomics trial at the BC Cancer (Clinicaltrials.gov ID:NCT02155621).
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